CEL-SCI Study Validates Multikine's Survival Benefit in Head and Neck Cancer — CEL-SCI Corporation

Event summary

CEL-SCI's study published in Oral Oncology shows Multikine improves five-year overall survival to 73.4% vs. 45.8% in head and neck cancer patients with low PD-L1 expression.
The study identifies low/zero tumor PD-L1 (TPS <10%) and no lymph node involvement as key biomarkers for patient selection.
Multikine's hazard ratio for overall survival is 0.34 (p=0.0012), with a 28.6% absolute improvement in five-year survival.
CEL-SCI plans to commence a global 212-patient Confirmatory Registration Study using the same biomarker-selected patient population.

The big picture

CEL-SCI's study provides peer-reviewed validation for its biomarker-driven approach to immunotherapy, addressing an underserved patient population with low PD-L1 expression. The findings position Multikine as a potential differentiator in the competitive head and neck cancer treatment landscape, where existing therapies primarily target high PD-L1 patients. The upcoming Confirmatory Registration Study will be critical in determining whether these results translate into regulatory approval and commercial success.

What we're watching

Clinical Validation: Whether the biomarker-selected patient population in the upcoming Confirmatory Registration Study replicates the survival benefits observed in the published study.
Regulatory Pathway: The pace at which CEL-SCI advances Multikine through regulatory approval, particularly given its Orphan Drug designation and the FDA's historical approval of Keytruda without established overall survival benefit.
Market Differentiation: How Multikine's unique mechanism targeting low/zero PD-L1 patients positions it against existing checkpoint inhibitors in head and neck cancer treatment.